Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Treatments

Reviewed as evidence on: Menopause timing / hormone therapy (estrogen-only) and dementia risk and AD neuropathology 7 studies (what the news said). Being listed means the study bears on the question, not that it agrees with the news.

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objectives Observational studies suggest reduced risk of Alzheimer disease (AD) in users of hormone therapy (HT), but trials show higher risk. We examined whether the association of HT with AD varies with timing or type of HT use. Methods Between 1995 and 2006, the population-based Cache County Study followed 1,768 women who had provided a detailed history on age at menopause and use of HT. During this interval, 176 women developed incident AD. Cox proportional hazard models evaluated the association of HT use with AD, overall and in relation to timing, duration of use, and type (opposed vs unopposed) of HT. Results Women who used any type of HT within 5 years of menopause had 30% less risk of AD (95% confidence interval 0.49-0.99), especially if use was for 10 or more years. By contrast, AD risk was not reduced among those who had initiated HT 5 or more years after menopause. Instead, rates were increased among those who began "opposed" estrogen-progestin compounds within the 3 years preceding the Cache County Study baseline (adjusted hazard ratio 1.93; 95% confidence interval 0.94-3.96). This last hazard ratio was similar to the ratio of 2.05 reported in randomized trial participants assigned to opposed HT. Conclusions Association of HT use and risk of AD may depend on timing of use. Although possibly beneficial if taken during a critical window near menopause, HT (especially opposed compounds) initiated in later life may be associated with increased risk. The relation of AD risk to timing and type of HT deserves further study.

What this study adds

Evidence grade: High

This is a trial. In 1,768 women followed in the Cache County Study, those who started any hormone therapy within 5 years of menopause had 30% less risk of Alzheimer's disease (95% CI 0.49–0.99), while those who started 5 or more years later saw no reduction. Women who began combined estrogen-progestin therapy in later life had higher rates (hazard ratio 1.93, though the 95% CI of 0.94–3.96 includes no effect), similar to the 2.05 ratio reported in randomized trials.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Shao, H., Breitner, J. C., Whitmer, R. A., Wang, J., Hayden, K., Wengreen, H., et al. (2012). Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology. https://doi.org/10.1212/wnl.0b013e318271f823

Vancouver

Shao H, Breitner JC, Whitmer RA, Wang J, Hayden K, Wengreen H, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology. 2012. doi:10.1212/wnl.0b013e318271f823. PMID: 23100399.

BibTeX

@article{shao2012-23100399,
  author  = {Shao, H. and Breitner, J. C. and Whitmer, R. A. and Wang, J. and Hayden, K. and Wengreen, H. and Corcoran, C. and Tschanz, J. and others},
  title   = {{Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study}},
  journal = {Neurology},
  year    = {2012},
  doi     = {10.1212/wnl.0b013e318271f823},
  pmid    = {23100399},
  url     = {https://doi.org/10.1212/wnl.0b013e318271f823}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In 1,768 women followed in the Cache County Study, those who started any hormone therapy within 5 years of menopause had 30% less risk of Alzheimer's disease (95% CI 0.49–0.99), while those who started 5 or more years later saw no reduction. Women who began combined estrogen-progestin therapy in later life had higher rates (hazard ratio 1.93, though the 95% CI of 0.94–3.96 includes no effect), similar to the 2.05 ratio reported in randomized trials. Because this is an observational study, it suggests timing may matter. It does not show that hormone therapy prevents Alzheimer's.

Study details

How this study scored 68/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 1 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 68 of 100.68 of 100 points earned32 not earned

Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2012 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 5 / 7 Cited 261 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 16.3 citations a year over 16 year(s) since 2012
Impact for its field and year 4 / 6 Cited 15.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 11 other studies in this library
Still being cited 2 / 4 Cited 40 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Bonita W. Wyse: h-index 29 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 15 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 23100399)
Free to read 0 / 2 Behind a paywall — scores zero
Total 68 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Treatments from nearby years

Also tagged “menopause-hrt-and-dementia”

7 studies in the library carry the topic tag “menopause-hrt-and-dementia”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 7 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →